Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05029973 | HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05225116 | Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT | unknown | Phase 1 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 8, 2023 |
| clinicaltrials |
| NCT05716620 | Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 380 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03099564 | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | unknown | Early Phase 1 | 30 | Ashwin SomasundaramOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04911959 | Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC | unknown | Phase 1 / Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05466357 | Application Research on Endoscopic Pseudocapsule-Based Resection for Pituitary Adenomas | unknown | N/A | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05185557 | BRIANSTORM - Early Identification of Patients With Brain Metastases | unknown | — | 50 | Aarhus University HospitalOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT05578170 | Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma(PROBES) | unknown | — | 47 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT04605237 | Pancreatic Cancer Recurrence in the Netherlands | unknown | — | 1,750 | UMC UtrechtOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT04612504 | SynOV1.1 Intratumoral Injection Study | unknown | Phase 1 | 15 | Beijing Syngentech Co., Ltd.INDUSTRY | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05701553 | Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma | unknown | — | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05609695 | Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma | unknown | — | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05705583 | A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma | unknown | — | 100 | Zhejiang Cancer HospitalOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05705635 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | unknown | Phase 2 | 100 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05707338 | Short-term Outcomes of Laparoscopic Versus Open Gastrectomy With Lymph Node Dissection for Early Gastric Cancer :a Randomized Controlled Study | unknown | N/A | 40 | Sohag UniversityOTHER | 0 | Jan 31, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05131698 | Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | unknown | Early Phase 1 | 31 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05312216 | Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 25 | Zhejiang UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05693519 | GastroIntestinal Cancer in Children and Adolescents(GICCA) | unknown | — | 2,500 | Paul G. Kemps, MDOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05692661 | A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer | unknown | Phase 1 | 24 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04248998 | Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer(BREAKFAST) | unknown | Phase 2 | 30 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04582968 | Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases | unknown | Phase 1 / Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04213118 | Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence(ALTER-H-004) | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05686720 | Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer | unknown | Early Phase 1 | 12 | First Affiliated Hospital of Shantou University Medical CollegeOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05043532 | Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer | unknown | N/A | 33 | Orlando Health, Inc.OTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05680662 | The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism | unknown | Early Phase 1 | 200 | Ministry of Health, Saudi ArabiaOTHER_GOV | 0 | Jan 11, 2023 | clinicaltrials |
| NCT05677724 | Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment | unknown | — | 20 | Fubing WangOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
| NCT05668767 | Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC | unknown | Phase 2 | 20 | Beijing Chest HospitalOTHER | 0 | Dec 30, 2022 | clinicaltrials |
| NCT05668793 | GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method) | unknown | — | 1,000 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 0 | Dec 30, 2022 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05557656 | A Real World Study of Regogfinib in HCC | unknown | — | 800 | Zhongda HospitalOTHER | 0 | Dec 29, 2022 | clinicaltrials |
| NCT05631613 | Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma | unknown | — | 40 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05662488 | FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy | unknown | — | 25 | Peking Union Medical College HospitalOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05660889 | Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma(AVS for ACC) | unknown | — | 25 | Erasmus Medical CenterOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05649163 | Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | unknown | — | 306 | Shen LinOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05578430 | AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 0 | Dec 15, 2022 | clinicaltrials |
| NCT05361538 | Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm | unknown | N/A | 60 | Tianjin Third Central HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05650151 | Peri-operative Vitamin D Therapy for Hepatectomy | unknown | N/A | 200 | National Taiwan University HospitalOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT05650216 | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT） | unknown | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04212273 | Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC | unknown | N/A | 200 | Tianjin Third Central HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT02446366 | Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery | unknown | N/A | 24 | University of Southern CaliforniaOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT05557851 | Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas | unknown | Phase 1 | 36 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05638256 | 68Ga-labeled NY104 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05636150 | A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 48 | Peking Union Medical College HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | unknown | Phase 2 | 63 | Hunan Cancer HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05633641 | Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma | unknown | — | 60 | Fudan UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 8, 2023source: clinicaltrials